From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Optibiotix – when will the business momentum turn into share price action?

By Nigel Somerville | Monday 5 October 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I have a small holding in AIM-listed Optibiotix (OPTI) – perhaps Tom Winnifrith’s favourite stock. It has been a wild ride, with the shares having headed above £1 a pop but the stock has certainly been in the doldrums recently, having tested 50p over the summer and has now perked up to just 63p. Yet we are getting an extended flurry of contracts and deals which should transform this business, which as far as I can see has little issue over cash whilst we await the mega-profits promised. What gives?…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ANP

Anpario – a recovery Buy?...

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 17:01:16